240 related articles for article (PubMed ID: 23341861)
1. Immunotherapy of human papilloma virus induced disease.
van der Burg SH
Open Virol J; 2012; 6():257-63. PubMed ID: 23341861
[TBL] [Abstract][Full Text] [Related]
2. Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients.
McCormack SE; Cruz CRY; Wright KE; Powell AB; Lang H; Trimble C; Keller MD; Fuchs E; Bollard CM
Cytotherapy; 2018 Mar; 20(3):385-393. PubMed ID: 29331266
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy against cancer-related viruses.
Tashiro H; Brenner MK
Cell Res; 2017 Jan; 27(1):59-73. PubMed ID: 28008927
[TBL] [Abstract][Full Text] [Related]
4. Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer.
de Jong A; van der Hulst JM; Kenter GG; Drijfhout JW; Franken KL; Vermeij P; Offringa R; van der Burg SH; Melief CJ
Int J Cancer; 2005 Mar; 114(2):274-82. PubMed ID: 15540211
[TBL] [Abstract][Full Text] [Related]
5. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma.
Chen Z; Dong D; Zhu Y; Pang N; Ding J
FASEB J; 2021 Mar; 35(3):e21401. PubMed ID: 33559190
[TBL] [Abstract][Full Text] [Related]
6. Targeting HPV in gynaecological cancers - Current status, ongoing challenges and future directions.
Crusz SM; El-Shakankery K; Miller RE
Womens Health (Lond); 2020; 16():1745506520961709. PubMed ID: 33296284
[TBL] [Abstract][Full Text] [Related]
7. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.
Scholten KB; Turksma AW; Ruizendaal JJ; van den Hende M; van der Burg SH; Heemskerk MH; Meijer CJ; Hooijberg E
J Transl Med; 2011 Sep; 9():147. PubMed ID: 21892941
[TBL] [Abstract][Full Text] [Related]
8. Host immune responses to cervical cancer.
Patel S; Chiplunkar S
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):54-9. PubMed ID: 19125004
[TBL] [Abstract][Full Text] [Related]
9. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions.
Seresini S; Origoni M; Lillo F; Caputo L; Paganoni AM; Vantini S; Longhi R; Taccagni G; Ferrari A; Doglioni C; Secchi P; Protti MP
J Immunol; 2007 Nov; 179(10):7176-83. PubMed ID: 17982110
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccination against human papilloma virus induced malignancies.
van der Burg SH; Melief CJ
Curr Opin Immunol; 2011 Apr; 23(2):252-7. PubMed ID: 21237632
[TBL] [Abstract][Full Text] [Related]
13. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells.
Luckau S; Wehrs TP; Brandau S; Horn PA; Lindemann M
J Immunother; 2016 Oct; 39(8):316-20. PubMed ID: 27548034
[TBL] [Abstract][Full Text] [Related]
14. Control of immune escaped human papilloma virus is regained after therapeutic vaccination.
Ma W; Melief CJ; van der Burg SH
Curr Opin Virol; 2017 Apr; 23():16-22. PubMed ID: 28282583
[TBL] [Abstract][Full Text] [Related]
15. HPV-specific immunotherapy: key role for immunomodulators.
Van de Wall S; Nijman HW; Daemen T
Anticancer Agents Med Chem; 2014 Feb; 14(2):265-79. PubMed ID: 24237218
[TBL] [Abstract][Full Text] [Related]
16. The current status of immunotherapy for cervical cancer.
Orbegoso C; Murali K; Banerjee S
Rep Pract Oncol Radiother; 2018; 23(6):580-588. PubMed ID: 30534022
[TBL] [Abstract][Full Text] [Related]
17. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC.
Williams R; Lee DW; Elzey BD; Anderson ME; Hostager BS; Lee JH
Head Neck; 2009 Jul; 31(7):911-8. PubMed ID: 19283850
[TBL] [Abstract][Full Text] [Related]
18. The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4
Adhikary D; Damaschke J; Mautner J; Behrends U
J Virol; 2020 Jul; 94(15):. PubMed ID: 32461311
[TBL] [Abstract][Full Text] [Related]
19. Human Papillomavirus Induced Cervical and Oropharyngeal Cancers: From Mechanisms to Potential Immuno-therapeutic Strategies.
Saeed M; Faisal SM; Akhtar F; Ahmad S; Alreshidi MM; Kausar MA; Kazmi S; Saeed A; Adnan M; Ashraf GM
Curr Drug Metab; 2020; 21(3):167-177. PubMed ID: 32316888
[TBL] [Abstract][Full Text] [Related]
20. Are macrophages the heroes or villains during cryptococcosis?
Rudman J; Evans RJ; Johnston SA
Fungal Genet Biol; 2019 Nov; 132():103261. PubMed ID: 31415906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
